{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:56:44Z","timestamp":1793303804210,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cmi.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:08:20Z","timestamp":1783919300000},"page":"1620-1634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reporting of antibiotic resistance in randomized controlled trials of new antibiotics: a systematic review"],"prefix":"10.1016","volume":"32","author":[{"given":"Itay","family":"Zahavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Tafesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimrod","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha K.","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ili","family":"Margalit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mical","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.07.002_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12992-025-01109-4","article-title":"Reserve antibiotics: Overcoming limitations of evidence generated from regulatory approval trials","volume":"21","author":"Moja","year":"2025","journal-title":"Glob Health"},{"key":"10.1016\/j.cmi.2026.07.002_bib2","series-title":"Analysis of antibacterial agents in clinical and preclinical development: Overview and analysis","year":"2025"},{"key":"10.1016\/j.cmi.2026.07.002_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.100992","article-title":"Addressing urgent priorities in antibiotic development: Insights from WHO 2023 antibacterial clinical pipeline analyses","volume":"6","author":"Melchiorri","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2026.07.002_bib4","series-title":"Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections","year":"2022"},{"key":"10.1016\/j.cmi.2026.07.002_bib5","series-title":"Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases","year":"2017"},{"key":"10.1016\/j.cmi.2026.07.002_bib6","series-title":"Microbiological data for systemic antibacterial drug products \u2014 development, analysis, and presentation","year":"2025"},{"key":"10.1016\/j.cmi.2026.07.002_bib7","series-title":"Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases \u2013 questions and answers","year":"2022"},{"key":"10.1016\/j.cmi.2026.07.002_bib8","series-title":"Uncomplicated urinary tract infections: Developing drugs for treatment, guidance for industry","year":"2019"},{"key":"10.1016\/j.cmi.2026.07.002_bib9","series-title":"Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: Developing drugs for treatment, guidance for industry","year":"2014"},{"key":"10.1016\/j.cmi.2026.07.002_bib10","series-title":"Complicated urinary tract infections: Developing drugs for treatment, guidance for industry","year":"2018"},{"key":"10.1016\/j.cmi.2026.07.002_bib11","series-title":"Acute bacterial skin and skin structure Infections: Developing drugs for treatment","year":"2013"},{"key":"10.1016\/j.cmi.2026.07.002_bib12","series-title":"Community-acquired bacterial pneumonia: Developing drugs for treatment guidance for industry","year":"2020"},{"key":"10.1016\/j.cmi.2026.07.002_bib13","series-title":"Complicated intra-abdominal infections: Developing drugs for treatment","year":"2018"},{"key":"10.1016\/j.cmi.2026.07.002_bib14","series-title":"Report on clinical evaluation of antimicrobial agents for AMR (Subcommittee on AMR of the Science Board)","year":"2019"},{"key":"10.1016\/j.cmi.2026.07.002_bib15","series-title":"Antibacterial agents in clinical and preclinical development: An overview and analysis 2023","year":"2023"},{"key":"10.1016\/j.cmi.2026.07.002_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.cmi.2026.07.002_bib17","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2026.07.002_bib18","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/cid\/ciw490","article-title":"SOLITAIRE-IV: A randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia","volume":"63","author":"File","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: A global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib21","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: A randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.cmi.2026.07.002_bib23","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: A phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: Results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib25","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.07.002_bib26","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: A phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib27","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: The TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.07.002_bib28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem\u2013vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: The TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2026.07.002_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01989-17","article-title":"A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis","volume":"62","author":"Connolly","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A Comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: A phase 3, multinational, double-blind, randomized study","volume":"67","author":"O\u2019Riordan","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.07.002_bib32","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.07.002_bib33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/OLQ.0000000000000971","article-title":"Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: An open-label, noninferiority, phase 3, multicenter, randomized study","volume":"46","author":"Hook","year":"2019","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib34","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O\u2019Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.07.002_bib35","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): A phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O\u2019Riordan","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib36","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/cid\/ciz090","article-title":"Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: The phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) trial","volume":"69","author":"File","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib37","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.2019.15468","article-title":"Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: The LEAP 2 randomized clinical trial","volume":"322","author":"Alexander","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.07.002_bib38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.07.002_bib39","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1473-3099(19)30116-1","article-title":"Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): A randomised Phase 3 non-inferiority trial","volume":"19","author":"Chen","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00250-20","article-title":"Afabicin, a first-in-class antistaphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: Clinical noninferiority to vancomycin\/linezolid","volume":"64","author":"Wittke","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib42","first-page":"ofz514","article-title":"A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01506-19","article-title":"Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis","volume":"64","author":"Sagan","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib44","doi-asserted-by":"crossref","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: Results of a phase 3, randomized, double-blind trial (TARGET)","volume":"73","author":"Overcash","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib45","first-page":"30","article-title":"Efficacy and safety of a novel broad-spectrum anti-MRSA agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: A phase 3, openlabel, randomized study","volume":"68","author":"Bhatia","year":"2020","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.cmi.2026.07.002_bib46","first-page":"255","article-title":"Phase III double-blind comparative study of intravenous lascufloxacin and levofloxacin in patients with community-acquired pneumonia","volume":"69","author":"Miki","year":"2021","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib47","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib48","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib50","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1097\/INF.0000000000003077","article-title":"A phase 3, randomized, investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients","volume":"40","author":"Bosheva","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2026.07.002_bib51","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa2105462","article-title":"Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection","volume":"386","author":"Eckburg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.07.002_bib52","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/jac\/dkac073","article-title":"A phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections","volume":"77","author":"Zhao","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/cid\/ciac738","article-title":"Sulopenem or ciprofloxacin for the treatment of uncomplicated urinary tract infections in women: A phase 3, randomized trial","volume":"76","author":"Dunne","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib54","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: A randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.07.002_bib55","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.07.002_bib56","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/INF.0000000000003559","article-title":"Solithromycin in children and adolescents with community-acquired bacterial pneumonia","volume":"41","author":"Lang","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2026.07.002_bib57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/cid\/ciac704","article-title":"Sulopenem for the treatment of complicated urinary tract infections including pyelonephritis: A phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib58","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib59","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1093\/jac\/dkae254","article-title":"A randomized non-inferiority study comparing imipenem\/cilastatin\/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia","volume":"79","author":"Chaftari","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib60","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): Two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.07.002_bib61","first-page":"1938","article-title":"Cefepime-taniborbactam in complicated urinary tract infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"Reply. N Engl J Med."},{"key":"10.1016\/j.cmi.2026.07.002_bib62","first-page":"249","article-title":"Efficacy and safety of eravacycline versus ertapenem in the treatment of complicated intraperitoneal infection in Chinese adults: A multicenter, randomized, double-blind phase III bridging trial","volume":"24","author":"L\u00fc","year":"2024","journal-title":"Chin J Infect Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib63","doi-asserted-by":"crossref","first-page":"dlaf131","DOI":"10.1093\/jacamr\/dlaf131","article-title":"Aztreonam-avibactam for the treatment of serious infections caused by metallo-\u03b2-lactamase-producing Gram-negative pathogens: A phase 3 randomized trial (ASSEMBLE)","volume":"7","author":"Daikos","year":"2025","journal-title":"JAC-Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.07.002_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107357","volume":"153","author":"Li","year":"2025","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib65","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): A phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.07.002_bib66","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cmi.2024.10.025","article-title":"A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections","volume":"31","author":"Dunne","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.07.002_bib67","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400414","article-title":"Sulopenem versus amoxicillin\/clavulanate for the treatment of uncomplicated urinary tract infection","volume":"4","author":"Puttagunta","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.cmi.2026.07.002_bib68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(25)00469-4","article-title":"Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): An open-label, parallel-group, randomised trial","volume":"26","author":"Paterson","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib69","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(25)01953-1","article-title":"Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: An international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial","volume":"407","author":"Luckey","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.07.002_bib70","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/sextrans-2024-056338","article-title":"Lefamulin for Mycoplasma genitalium treatment failure in Australia and the USA: A case series and pilot open-label parallel arm randomised trial","volume":"101","author":"Ramchandani","year":"2025","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.cmi.2026.07.002_bib71","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): A descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib72","article-title":"Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: A phase III, randomized, double-blind controlled trial","volume":"41","author":"Pophale","year":"2025","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"10.1016\/j.cmi.2026.07.002_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2025.102829","article-title":"Oral gepotidacin for the treatment of uncomplicated urinary tract infection in Japanese female patients: A randomized, active reference, double-blind, double-dummy, phase 3 trial (EAGLE-J)","volume":"32","author":"Yamamoto","year":"2026","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib74","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00236-24","article-title":"Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection","volume":"68","author":"Moeck","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib75","article-title":"Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: Results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3)","volume":"69","author":"Scangarella-Oman","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib76","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01698-23","article-title":"Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)","volume":"68","author":"Miller","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib77","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01949-19","article-title":"Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Microbiology results from the delafloxacin phase 3 CABP trial","volume":"64","author":"McCurdy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib78","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jgar.2021.10.021","article-title":"Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin","volume":"29","author":"Paukner","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.07.002_bib79","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00772-17","article-title":"In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections","volume":"61","author":"McCurdy","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib80","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx163.1404","article-title":"Assessment of MIC increases with meropenem-vaborbactam and ceftazidime-avibactam in TANGO II (a phase 3 study of the treatment of CRE infections)","volume":"4","author":"Lomovskaya","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib81","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03361-25","article-title":"Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for methicillin-resistant Staphylococcus aureus bacteremia: A multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial","volume":"14","author":"Park","year":"2026","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2026.07.002_bib82","series-title":"Tetraphase Pharmaceuticals, Inc. A phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections","year":"2021"},{"key":"10.1016\/j.cmi.2026.07.002_bib83","doi-asserted-by":"crossref","first-page":"dlad011","DOI":"10.1093\/jacamr\/dlad011","volume":"5","author":"Roberts","year":"2023","journal-title":"JAC-Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.07.002_bib84","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cmi.2024.09.025","article-title":"Introducing new antibiotics for multidrug-resistant bacteria: Obstacles and the way forward","volume":"31","author":"T\u00e4ngd\u00e9n","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.07.002_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045406","article-title":"Reporting of adverse events, conflict of interest and funding in randomised controlled trials of antibiotics: A secondary analysis","volume":"11","author":"Bakhit","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2026.07.002_bib86","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkg409","article-title":"Considering resistance in systematic reviews of antibiotic treatment","volume":"52","author":"Leibovici","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib87","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/jac\/dkw135","article-title":"Addressing resistance to antibiotics in systematic reviews of antibiotic interventions","volume":"71","author":"Leibovici","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.07.002_bib88","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/S1473-3099(25)00501-8","article-title":"The emerging resistance index: Tracking early resistance to new antibiotics","volume":"26","author":"Garlasco","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib89","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","article-title":"The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach","volume":"18","author":"Mouton","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.07.002_bib90","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/cid\/ciaa930","article-title":"investigator-initiated randomized controlled trials in infectious diseases: Better value for money for registration trials of new antimicrobials","volume":"72","author":"Paul","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009956","article-title":"Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): A study protocol 2016","volume":"6","author":"Dickstein","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2026.07.002_bib92","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.cmi.2026.01.031","article-title":"Resistance development to new anti-Gram negatives antibiotics during treatment: Geographical epidemiology and risk factors","volume":"32","author":"Falcone","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.07.002_bib93","doi-asserted-by":"crossref","first-page":"e1696","DOI":"10.1093\/cid\/ciaa1353","article-title":"Methodological and reporting quality of noninferiority randomized controlled trials comparing antibiotic therapies: A systematic review","volume":"73","author":"Bai","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.002_bib94","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12874-021-01260-7","article-title":"Intention-to-treat analysis may be more conservative than per protocol analysis in antibiotic non-inferiority trials: A systematic review","volume":"21","author":"Bai","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cmi.2026.07.002_bib95","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2666-5247(23)00071-X","article-title":"Antimicrobial susceptibility assays for Neisseria gonorrhoeae: A proof-of-principle population-based retrospective analysis","volume":"4","author":"Bell","year":"2023","journal-title":"Lancet Microbe"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26003666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26003666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:10:35Z","timestamp":1790035835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26003666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":95,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1198743X26003666"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.07.002","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reporting of antibiotic resistance in randomized controlled trials of new antibiotics: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}